For example, cancers with the proliferation signature, characterized by p53 and PTEN inactivation and concomitant Myc activation, correlates with poor outcome in lung, prostate, breast and brain cancer, whereas remodeling signature, characterized by RAS, HIF-1α and NFκB activation, increases mortality rates in colorectal and ovarian cancer [39, 40]. This evidence concerns the gene MYC and brain cancer.